Form 4: Charles River Labs Exec Knell Reports Stock Activity

Charles River Laboratories' CSVP, CAO, and Interim CFO Michael Knell reported the acquisition of 1,668 shares and disposition of 526 shares of common stock.

Summary

• Michael G. Knell, CSVP, CAO, and Interim CFO of Charles River Laboratories International, Inc. (CRL), reported transactions in the company's common stock.
• Knell acquired 1,668 shares of common stock on January 30, 2026, at a price of $0 per share.
• These acquired shares were issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023.
• Knell also disposed of 526 shares of common stock on January 30, 2026, at a price of $211.68 per share.
• Following these reported transactions, Knell's direct beneficial ownership of common stock stands at 14,602 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting the routine vesting of performance-based compensation and the achievement of underlying performance goals, which is a standard part of executive incentive programs.

Positives

• Michael G. Knell acquired 1,668 shares of common stock due to the achievement of performance goals for previously granted performance share unit awards, indicating successful performance against set metrics.

Negatives

• Michael G. Knell disposed of 526 shares of common stock at $211.68 per share, which is a common practice for tax withholding purposes upon the vesting of equity awards.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to the vesting of performance-based equity awards and subsequent sales for tax withholding, are routine occurrences in the life sciences and pharmaceutical sectors. These events provide transparency into executive compensation structures and the achievement of internal performance metrics.

Comparison to Industry Standards

• The vesting of performance share units and the subsequent sale of shares for tax withholding purposes by executives is a standard compensation practice across the biotechnology and pharmaceutical industries, comparable to practices at companies like LabCorp (LH) or IQVIA (IQV).
• The $0 acquisition price for performance-based awards is typical for equity compensation plans designed to align executive incentives with company performance and is a common feature in executive compensation packages across various sectors.

Stakeholder Impact

• Shareholders: Provides transparency into executive compensation and ownership, indicating that performance goals for equity awards were met, which can be a positive signal regarding company performance.
• Employees: Reflects standard executive compensation practices, potentially signaling confidence in company performance and the effectiveness of incentive programs.

Key Dates

Keywords

Charles River Laboratories, CRL, Michael Knell, Form 4, insider transaction, stock acquisition, performance shares, executive compensation